BIOCRYST PHARMACEUTICALS INC (BCRX) › Shares OutstandingBIOCRYST PHARMACEUTICALS INC (BCRX) — Shares OutstandingAnnual figures by period end, from SEC filings.2010-12-31: 44.96M2011-12-31: 45.66M2012-12-31: 50.89M2013-12-31: 59.09M2014-12-31: 71.95M2015-12-31: 73.36M2016-12-31: 73.78M2017-12-31: 98.41M2018-12-31: 110.06M2019-12-31: 154.08M2020-12-31: 176.88M2021-12-31: 184.35M2022-12-31: 187.91M2023-12-31: 205.77M2024-12-31: 208.54M2025-12-31: 213.06M213.06M2010-12-31Shares Outstanding (shares)2025-12-31Period endedShares OutstandingChange YoYSource filing2025-12-31213.06M+2.2%2026-02-26Balance as of period end2024-12-31208.54M+1.3%2026-02-26Balance as of period end2023-12-31205.77M+9.5%2025-02-25Balance as of period end2022-12-31187.91M+1.9%2024-02-27Balance as of period end2021-12-31184.35M+4.2%2023-02-27Balance as of period end2020-12-31176.88M+14.8%2022-02-28Balance as of period end2019-12-31154.08M+40.0%2021-03-01Balance as of period end2018-12-31110.06M+11.8%2020-03-13Balance as of period end2017-12-3198.41M+33.4%2019-03-14Balance as of period end2016-12-3173.78M+0.6%2018-03-12Balance as of period end2015-12-3173.36M+1.9%2017-02-27Balance as of period end2014-12-3171.95M+21.8%2016-02-26Balance as of period end2013-12-3159.09M+16.1%2015-03-02Balance as of period end2012-12-3150.89M+11.5%2014-03-10Balance as of period end2011-12-3145.66M+1.6%2013-03-11Balance as of period end2010-12-3144.96M—2012-03-06Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresDividends Per ShareWeighted Average Diluted SharesEPS (Basic)